Get the latest scoop on medical tech breakthroughs, healthcare policy shifts, and essential clinical research news delivered daily.
The South Korean medical device industry is at a turning point driven by regulatory shifts and innovation. The FDA's move to ease oversight on AI and wearables, combined with Samsung's enhanced AI health watches, is accelerating global competition. Meanwhile, local challenges like medical professional training controversies and barriers to clinical adoption for digital healthcare remain critical hurdles.
The South Korean MFDS has eased regulations on autologous NK cell therapy to accelerate clinical entry, while Classys prepares for global expansion with a new CEO from Samsung Electronics. Meanwhile, the FDA continues to relax monitoring for AI medical devices and wearables, opening new paths for South Korean startups to enter the U.S. market.
The upcoming launch of the AI-powered Galaxy Watch 9 and the FDA’s move to relax AI medical device regulations are reshaping the global market. With the first LLM-based software cleared for 510(k) in the U.S., South Korean firms should leverage the 240-day fast-track approval system by the MFDS to accelerate their global expansion.
As the Korean medical device industry gains global competitiveness through expanded rapid approval systems and streamlined digital health regulations, the U.S. FDA’s move to ease regulations on wearable and AI devices is creating new opportunities for Korean firms. With the global AI medical device market projected to reach $84.8 billion by 2033, international competition among Korean digital therapeutics and AI diagnostic startups is intensifying.
The South Korean MFDS has finalized a 240-day approval pathway for innovative medical devices, while the FDA is easing regulations on AI wearables. This creates a critical window for Korean companies to leverage regulatory improvements for global expansion.
한국 식약처(MFDS)가 혁신의료기기 허가 체계를 240일로 확정하며 시장 진입 속도를 높이고 있습니다. 미국 FDA는 생성형 AI 기반 의료기기 규제를 완화하고 있어, 국내 AI 의료기기 기업들의 해외 진출 가능성이 커졌습니다. 지아이비타와 같은 디지털 헬스케어 스타트업의 투자 유치도 활발해지며 산업의 혁신 흐름이 지속되고 있습니다.
The MFDS has finalized a 240-day fast-track for innovative medical devices, helping speed up local regulations. Meanwhile, the FDA’s easing of AI and wearable device rules is opening doors for South Korean startups. With pharmaceutical and medical device companies increasingly collaborating on digital health, success now hinges on regulatory advancement and real-world data collection.
The FDA is driving the AI medical device market by approving cardiovascular disease detection and ECG-based diagnostic tools. The Korean medical device industry is boosting global competitiveness by increasing the number of designated innovative medical technologies (45 cases in 2025, up 50% YoY) and streamlining market entry. The trend toward easing AI regulations in the U.S. is expected to broaden expansion opportunities for Korean firms.
The South Korean medical device sector is sharpening its global edge through faster market entry and more innovative product designations. Simultaneously, the US FDA is loosening regulations on AI devices and wearables, creating a smoother path for Korean exports. Meanwhile, the $20 billion Korean aesthetic medical device market (HIFU, RF) is attracting significant interest from global private equity firms, with companies like Classys and Wontech leading the charge.
삼성메디슨 is accelerating its global expansion by supplying ultrasound devices to major U.S. hospitals, while South Korean aesthetic device makers (Classys, Wontech, Jeisys) are emerging as key players in a $2B market. Meanwhile, FDA deregulation of AI and wearables is opening doors for South Korean digital health startups.
The South Korean aesthetic medical device sector is booming as global private equity firms take notice, while tougher GMP regulations from the MFDS are keeping manufacturers on their toes. Meanwhile, the U.S. FDA's eased rules on AI medical devices and wearables are opening new doors for Korean digital health companies.
The South Korean aesthetic medical device industry is attracting significant global PE interest, while the MFDS pushes forward with AI medical device regulatory innovation. Furthermore, the U.S. FDA's easing of AI and wearable regulations is opening doors for South Korean MedTech companies to expand overseas.
The Korean aesthetic medical device market is hitting a $2B valuation, attracting major global Private Equity firms. Meanwhile, FDA deregulation on AI and wearables is set to fast-track Korean companies' global expansion, as Samsung Health revamps its AI wellness features to reshape the digital health ecosystem.
South Korea's medical device industry is keeping its momentum with six consecutive years of trade surpluses and a rise in innovative technology designations. Meanwhile, the U.S. FDA’s relaxation of AI device regulations is opening doors for Korean companies abroad, especially as Samsung enhances its AI health platform and wearable technology to stay ahead in the global market.
The Korean medical device industry grew by 8.1% in 2025 to 12.36 trillion won, marking a 6-year trade surplus streak. FDA deregulation regarding AI and wearables is providing a major boost to Korean firms like Samsung and LG, while the MFDS is accelerating market access for startups through expanded "innovative medical technology" designations and new fast-track paths.
South Korea's medical device industry maintains a trade surplus for the sixth straight year. Meanwhile, global competition in digital health is heating up, fueled by GE Healthcare's FDA-cleared AI oncology software and Samsung's AI-enhanced Galaxy Watch. Domestic startup GIBITA has also secured 4.5 billion won in Series A funding, accelerating the growth of the digital health ecosystem.
As Korea’s medical device industry celebrates six years of trade surpluses, global digital health markets are seeing a relaxation in AI medical device regulations. Competition in wearables is heating up with Samsung’s new Galaxy Watch AI Health Suite, while GE HealthCare’s FDA clearance for AI radiation therapy software opens doors for Korean AI firms to expand globally.
South Korea's medical device sector achieved its sixth consecutive year of trade surplus in 2025, demonstrating strong global competitiveness. With Samsung integrating AI health management suites into the Galaxy Watch and the U.S. FDA significantly relaxing regulations on AI medical devices and wearables, Korean companies are gaining expanded opportunities for international expansion.
The global medical device regulatory market is projected to reach $15.94 billion by 2035, with recent FDA guidelines easing regulations on AI and wearable devices offering a positive signal for the industry. While the Korean medical device sector has secured a trade surplus for six consecutive years, overcoming regulatory barriers and improving digital health reimbursement policies remain critical for sustainable growth.
Korea's medical device industry has posted a trade surplus for six consecutive years through 2025. With the MFDS tightening GMP audit rules while the FDA simplifies regulations for AI and wearables, local firms are accelerating their global expansion. Samsung Electronics is also stepping up its leadership in digital health by showcasing its AI-powered connected healthcare vision at VivaTech 2026.
Create custom signals on any topic. AI curates and delivers 24/7.
Create SignalPowered by
